| Daniel Nogee, MD | |
|
550 Peachtree St Ne, Atlanta, GA 30308-2212 | |
| (443) 803-3118 | |
| Not Available |
| Full Name | Daniel Nogee |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 550 Peachtree St Ne, Atlanta, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346586625 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 62551 (Connecticut) | Secondary |
| 207P00000X | Emergency Medicine | 86337 (Georgia) | Secondary |
| 207P00000X | Emergency Medicine | D96159 (Maryland) | Primary |
| Entity Name | Yale University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205822236 PECOS PAC ID: 9436061736 Enrollment ID: O20031105000015 |
News Archive
In his article, "Pathoetiology of multiple sclerosis: are we barking up the wrong tree?", Peter K. Stys of the Hotchkiss Brain Institute, University of Calgary, argues that while the majority of the medical research community currently approaches MS as an autoimmune disease (much like Lupus and Rheumatoid Arthritis), for which the trigger is the immune system attacking a particular part of the nervous system, the features of the disease are equally well explained by approaching MS as a neurodegenerative disease (such as Parkinson's and Alzheimer's), which is followed by an immune reaction to damage.
Today's headlines recap yesterday's Supreme Court action related to the constitutionality of the individual mandate and set the scene for day 3 of the oral arguments, which will tackle issues of severalbility and questions about the health law's Medicaid expansion.
A clinical trial conducted by researchers at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute, showed that a new drug called MM-398, given in combination with 5-flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously-treated pancreatic cancer.
BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Nogee, MD 6201 Greenleigh Ave, Middle River, MD 21220-2004 Ph: (410) 933-2704 | Daniel Nogee, MD 550 Peachtree St Ne, Atlanta, GA 30308-2212 Ph: (443) 803-3118 |
News Archive
In his article, "Pathoetiology of multiple sclerosis: are we barking up the wrong tree?", Peter K. Stys of the Hotchkiss Brain Institute, University of Calgary, argues that while the majority of the medical research community currently approaches MS as an autoimmune disease (much like Lupus and Rheumatoid Arthritis), for which the trigger is the immune system attacking a particular part of the nervous system, the features of the disease are equally well explained by approaching MS as a neurodegenerative disease (such as Parkinson's and Alzheimer's), which is followed by an immune reaction to damage.
Today's headlines recap yesterday's Supreme Court action related to the constitutionality of the individual mandate and set the scene for day 3 of the oral arguments, which will tackle issues of severalbility and questions about the health law's Medicaid expansion.
A clinical trial conducted by researchers at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute, showed that a new drug called MM-398, given in combination with 5-flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously-treated pancreatic cancer.
BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.
› Verified 5 days ago
Dr. Benjamin Aaron Levy, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 5665 New Northside Dr Nw, Suite 200, Atlanta, GA 30328 Phone: 770-874-5400 | |
Essi I Peers, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5665 New Northside Dr Ste 200, Atlanta, GA 30328 Phone: 770-874-5400 | |
Prince N Martin, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5665 Peachtree Dunwoody Rd, Atlanta, GA 30342 Phone: 678-843-7001 | |
Melissa H White, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 80 Jesse Hill Jr Dr Se, Atlanta, GA 30303 Phone: 404-616-4307 Fax: 404-616-8022 | |
John H Lloyd, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1358 Middlesex Ave Ne, Atlanta, GA 30306 Phone: 404-944-7563 | |
Dr. Vida M. Reklaitis, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 Johnson Ferry Rd Ne, Atlanta, GA 30342 Phone: 404-851-6936 Fax: 404-851-6024 | |
Dr. Steven M Joyce, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2292 Peachtree Rd., Nw, Atlanta, GA 30309 Phone: 801-558-7791 |